

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

Neuland secures development collaboration with LIR Life Sciences for transdermal GLP-1

06 May 2026 | News

CDMO to advance biotech's novel cell-penetrating peptides for next-generation obesity therapies



Hyderabad-based Neuland Laboratories, a global contract development and manufacturing organisation (CDMO) specialising in complex APIs, has entered into a development partnership with LIR Life Sciences Corp, a Canada-based biotechnology company focused on scalable and accessible obesity treatments, in advancing its cell-penetrating peptide (CPP) platform.

As part of this engagement, Neuland will develop, test, and manufacture CPPs to support pharmacokinetic (PK) and pharmacodynamic (PD) studies, as well as Phase I formulations for LIR Life's transdermal GLP-1/GIP programme.

LIR Life is developing a patch-based, transdermal delivery system for GLP-1 therapies targeting obesity. Unlike traditional injectable formulations, the platform is designed to enable non-invasive administration, with the potential to improve patient adherence and broaden access. Currently, there are no approved transdermal GLP-1 therapies, positioning this approach as a potentially significant innovation in the treatment landscape.

For Neuland, the partnership highlights its expanding capabilities in peptide development and manufacturing, particularly in complex and emerging modalities such as CPP-enabled delivery systems. The company supports peptide programs from early development through commercial scale, with integrated capabilities spanning process development, scale-up, and cGMP manufacturing.

The collaboration builds on Neuland's recent investments in peptide infrastructure, including a new \$20 million process development laboratory and a multi-phase commercial peptide manufacturing facility at its Bonthapally campus in Hyderabad. Module one of the peptide facility, representing an investment of approximately \$30 million and 6,370 litres of capacity, is expected to become operational by mid-2026.